首页 > 最新文献

Human Gene最新文献

英文 中文
Exploring non -coding RNAs contribution to neural tube defects 探索非编码rna在神经管缺陷中的作用
IF 0.7 Q4 GENETICS & HEREDITY Pub Date : 2026-01-05 DOI: 10.1016/j.humgen.2025.201528
Zahraa Isam Jameel
This review paper covers the diversified role of non-coding RNAs (ncRNAs) in the formation of neural tube defects (NTDs). NTDs are a group of serious birth defects that arise when the neural tube does not close normally during the early embryonic development. Although both genetic and environmental factors are known to cause neural tube defects (NTDs), the role of non-coding RNAs (ncRNAs) in the molecular mechanisms is becoming more evident. In this article, the different kinds of ncRNAs, such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), and their particular roles during neural tube closure will be discussed, focusing on their prospects as therapeutic targets for NTD prevention or treatment. Studies have revealed the role of specific microRNAs, such as members in the miR-17–92 and miR-100 clusters, in the regulation of essential processes, including the proliferation, differentiation, and death of neural precursor cells. The disruption of critical signaling, such as folate metabolism and planar cell polarity, affects these processes. Moreover, there has now become evidence on the role of lncRNAs and circRNAs in the interaction with chromatin-modification complexes, influencing the epigenetic profiles required during neural tube closure, and the regulation of gene expression through the ceRNA action. The developing embryo, whose ncRNA network has the disrupted ncRNA network, has an increased risk of developing the defects in the neural tubes. conclusion, NTD ncRNs represent an important area in the understanding and diagnosis of neural tube defects. The use of ncRNs, particularly some types of microRNs, long ncRNs, and circRNs, has proven that they are far from the “noise” transcribed in the genome. In fact, they play vital roles in the regulation of genes related to the closing of the neural tube. When ncRNs, including some microRNs, long ncRNs, and circRNs, malfunction, they disrupt vital signaling, resulting in an increased risk of the development of NTDs in the embryo. ncRNs link genetic risk and environment, contributing to the increased incidence that was unaccounted for. Future studies, therefore, shall focus on the use of ncRNs in the biomarkers needed in detecting the risk factors and risk of NTDs, the use of long ncRNs and circRNs, and the development of strategies in the prevention of congenital defects.
本文综述了非编码rna (ncRNAs)在神经管缺陷(NTDs)形成中的多种作用。ntd是一组严重的出生缺陷,当神经管在早期胚胎发育期间不能正常关闭时出现。虽然已知遗传和环境因素都可导致神经管缺陷(NTDs),但非编码rna (ncRNAs)在分子机制中的作用越来越明显。本文将讨论不同种类的ncRNAs,如microRNAs (miRNAs)、长链非编码rna (lncRNAs)和环状rna (circRNAs),以及它们在神经管闭合过程中的特殊作用,重点讨论它们作为NTD预防或治疗的治疗靶点的前景。研究揭示了特定的microrna,如miR-17-92和miR-100簇中的成员,在调节基本过程中的作用,包括神经前体细胞的增殖、分化和死亡。关键信号的破坏,如叶酸代谢和平面细胞极性,影响这些过程。此外,目前已有证据表明lncrna和circrna与染色质修饰复合物相互作用,影响神经管闭合过程中所需的表观遗传谱,并通过ceRNA作用调节基因表达。发育中的胚胎,其ncRNA网络有被破坏的ncRNA网络,在神经管中发生缺陷的风险增加。结论NTD ncrn是神经管缺损认识和诊断的重要领域。ncrn的使用,特别是某些类型的microrn、long ncrn和circrn,已经证明它们与基因组转录的“噪音”相去甚远。事实上,它们在调节与神经管闭合相关的基因中起着至关重要的作用。当ncrn,包括一些microrn、long ncrn和circrn发生故障时,它们会破坏生命信号,导致胚胎中ntd发育的风险增加。ncrn将遗传风险和环境联系起来,导致了未被解释的发病率增加。因此,未来的研究应侧重于ncrn在检测ntd危险因素和风险所需的生物标志物中的应用,长ncrn和环状ncrn的使用,以及先天性缺陷预防策略的制定。
{"title":"Exploring non -coding RNAs contribution to neural tube defects","authors":"Zahraa Isam Jameel","doi":"10.1016/j.humgen.2025.201528","DOIUrl":"10.1016/j.humgen.2025.201528","url":null,"abstract":"<div><div>This review paper covers the diversified role of non-coding RNAs (ncRNAs) in the formation of neural tube defects (NTDs). NTDs are a group of serious birth defects that arise when the neural tube does not close normally during the early embryonic development. Although both genetic and environmental factors are known to cause neural tube defects (NTDs), the role of non-coding RNAs (ncRNAs) in the molecular mechanisms is becoming more evident. In this article, the different kinds of ncRNAs, such as microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), and their particular roles during neural tube closure will be discussed, focusing on their prospects as therapeutic targets for NTD prevention or treatment. Studies have revealed the role of specific microRNAs, such as members in the miR-17–92 and miR-100 clusters, in the regulation of essential processes, including the proliferation, differentiation, and death of neural precursor cells. The disruption of critical signaling, such as folate metabolism and planar cell polarity, affects these processes. Moreover, there has now become evidence on the role of lncRNAs and circRNAs in the interaction with chromatin-modification complexes, influencing the epigenetic profiles required during neural tube closure, and the regulation of gene expression through the ceRNA action. The developing embryo, whose ncRNA network has the disrupted ncRNA network, has an increased risk of developing the defects in the neural tubes. conclusion, NTD ncRNs represent an important area in the understanding and diagnosis of neural tube defects. The use of ncRNs, particularly some types of microRNs, long ncRNs, and circRNs, has proven that they are far from the “noise” transcribed in the genome. In fact, they play vital roles in the regulation of genes related to the closing of the neural tube. When ncRNs, including some microRNs, long ncRNs, and circRNs, malfunction, they disrupt vital signaling, resulting in an increased risk of the development of NTDs in the embryo. ncRNs link genetic risk and environment, contributing to the increased incidence that was unaccounted for. Future studies, therefore, shall focus on the use of ncRNs in the biomarkers needed in detecting the risk factors and risk of NTDs, the use of long ncRNs and circRNs, and the development of strategies in the prevention of congenital defects.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"47 ","pages":"Article 201528"},"PeriodicalIF":0.7,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145924589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In utero gene therapy: Pioneering diagnostic and therapeutic technologies 子宫内基因治疗:开创性的诊断和治疗技术
IF 0.7 Q4 GENETICS & HEREDITY Pub Date : 2025-12-30 DOI: 10.1016/j.humgen.2025.201527
Shalmoli Seth , Malini Sen , Souvik Banerjee , Ritamay Sau , Somasree Ray
Advancements in prenatal imaging, molecular diagnostics, and genetic screening have transformed the management of congenital diseases, enabling early identification and treatment in utero. These innovations facilitate medical interventions before clinical symptoms arise, improving outcomes and reducing disease severity. Advanced genetic testing of blood, tissue, and other biological samples, combined with techniques such as fluorescence in situ hybridization and chromosomal microarray analysis, allows precise detection and classification of monogenic, mitochondrial, chromosomal, and multifactorial disorders. Emerging in utero therapies, particularly gene therapy, leverage the fetus's unique developmental properties to provide targeted and minimally invasive treatment for structural and genetic abnormalities. However, key challenges remain, such as ensuring biocompatibility and achieving efficient intracellular transgene delivery. Progress in viral and non-viral delivery systems and advancements in gene editing technologies have shown potential in overcoming these obstacles, paving the way for clinical translation. Nanotechnology further enhances these efforts by providing customizable, stable platforms for stage-specific and tissue-targeted interventions, broadening the scope of successful in utero treatments. Collectively, these advances in prenatal diagnostics and therapeutic strategies present an opportunity to address congenital disorders at their origin, significantly improving longterm health outcomes and quality of life by intervening at the earliest stages of development.
产前成像、分子诊断和遗传筛查方面的进步已经改变了先天性疾病的管理,能够在子宫内早期识别和治疗。这些创新有助于在临床症状出现之前进行医疗干预,改善结果并降低疾病严重程度。血液、组织和其他生物样本的先进基因检测,结合荧光原位杂交和染色体微阵列分析等技术,可以精确检测和分类单基因、线粒体、染色体和多因素疾病。新兴的子宫疗法,特别是基因疗法,利用胎儿独特的发育特性,为结构和遗传异常提供靶向和微创治疗。然而,关键的挑战仍然存在,如确保生物相容性和实现有效的细胞内转基因递送。病毒和非病毒传递系统的进展以及基因编辑技术的进步显示出克服这些障碍的潜力,为临床转化铺平了道路。纳米技术进一步加强了这些努力,为特定阶段和组织靶向干预提供了可定制的、稳定的平台,扩大了子宫内治疗成功的范围。总的来说,产前诊断和治疗战略方面的这些进展为从根源上解决先天性疾病提供了机会,通过在发育的早期阶段进行干预,显著改善长期健康结果和生活质量。
{"title":"In utero gene therapy: Pioneering diagnostic and therapeutic technologies","authors":"Shalmoli Seth ,&nbsp;Malini Sen ,&nbsp;Souvik Banerjee ,&nbsp;Ritamay Sau ,&nbsp;Somasree Ray","doi":"10.1016/j.humgen.2025.201527","DOIUrl":"10.1016/j.humgen.2025.201527","url":null,"abstract":"<div><div>Advancements in prenatal imaging, molecular diagnostics, and genetic screening have transformed the management of congenital diseases, enabling early identification and treatment in utero. These innovations facilitate medical interventions before clinical symptoms arise, improving outcomes and reducing disease severity. Advanced genetic testing of blood, tissue, and other biological samples, combined with techniques such as fluorescence in situ hybridization and chromosomal microarray analysis, allows precise detection and classification of monogenic, mitochondrial, chromosomal, and multifactorial disorders. Emerging in utero therapies, particularly gene therapy, leverage the fetus's unique developmental properties to provide targeted and minimally invasive treatment for structural and genetic abnormalities. However, key challenges remain, such as ensuring biocompatibility and achieving efficient intracellular transgene delivery. Progress in viral and non-viral delivery systems and advancements in gene editing technologies have shown potential in overcoming these obstacles, paving the way for clinical translation. Nanotechnology further enhances these efforts by providing customizable, stable platforms for stage-specific and tissue-targeted interventions, broadening the scope of successful in utero treatments. Collectively, these advances in prenatal diagnostics and therapeutic strategies present an opportunity to address congenital disorders at their origin, significantly improving longterm health outcomes and quality of life by intervening at the earliest stages of development.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"47 ","pages":"Article 201527"},"PeriodicalIF":0.7,"publicationDate":"2025-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of rs10414846, rs10421768, rs855791 and rs4820268 polymorphisms in iron-regulatory genes among Malaysian young adults rs10414846、rs10421768、rs855791和rs4820268多态性在马来西亚年轻人铁调控基因中的作用
IF 0.7 Q4 GENETICS & HEREDITY Pub Date : 2025-12-24 DOI: 10.1016/j.humgen.2025.201526
Jin-Rou Liew , Sing-Yan Looi , Keat-Wei Loo , Lai-Kuan Teh
Genetic variants involved in iron-regulatory pathways are important determinants of individual susceptibility to iron deficiency or anaemia. Genetic determinants including the hepcidin antimicrobial peptide (HAMP) and transmembrane serine protease 6 (TMPRSS6) genes play crucial roles in systemic iron regulation. This study investigated the relationship of four single nucleotide polymorphisms (SNPs) [HAMP rs10414846 (C > T), HAMP rs10421768 (A > G), TMPRSS6 rs855791 (A > G) and TMPRSS6 rs4820268 (G > A)] with haemoglobin (Hb), plasma hepcidin and serum iron levels among Malaysian young adults. A total of 183 unrelated participants aged 18 to 35 years were recruited. Genotyping was conducted using tetra-primer amplification refractory mutation system-polymerase chain reaction (Tetra-ARMS-PCR). Plasma hepcidin concentration and serum iron levels were detected using a human hepcidin ELISA kit and an iron colorimetric assay, respectively. Statistical analyses were performed with the Kruskal-Wallis and Mann-Whitney U tests, followed by general linear model (GLM) adjustments for covariates. Gene-gene interactions were analysed using the Pearson Chi-square (χ2) test. A significant difference was observed between TMPRSS6 rs855791 and plasma hepcidin concentration after adjustment (p = 0.039), where G allele carriers exhibited lower hepcidin concentration compared with AA homozygotes. No significant differences were observed for the other polymorphisms. Linkage disequilibrium (LD) analysis revealed strong intragenic correlations within HAMP and TMPRSS6, but no intergenic association. These findings highlighted TMPRSS6's regulatory role in iron homeostasis. This study provides the first population-specific evidence among Malaysian young adults, offering baseline genetic data to support future large-scale and personalised anaemia research.
参与铁调控途径的遗传变异是个体对缺铁或贫血易感性的重要决定因素。包括hepcidin抗菌肽(HAMP)和跨膜丝氨酸蛋白酶6 (TMPRSS6)基因在内的遗传决定因素在全身铁调控中起着至关重要的作用。本研究调查了马来西亚年轻人中四个单核苷酸多态性(snp) [HAMP rs10414846 (C >; T), HAMP rs10421768 (A >; G), TMPRSS6 rs855791 (A >; G)和TMPRSS6 rs4820268 (G >; A)]与血红蛋白(Hb),血浆hepcidin和血清铁水平的关系。总共招募了183名年龄在18到35岁之间的无血缘关系的参与者。采用四引物扩增难解突变系统-聚合酶链反应(tetrao - arms - pcr)进行基因分型。血浆hepcidin浓度和血清铁水平分别采用人hepcidin ELISA试剂盒和铁比色法检测。采用Kruskal-Wallis检验和Mann-Whitney U检验进行统计分析,然后对协变量进行一般线性模型(GLM)调整。采用Pearson χ2检验分析基因-基因相互作用。调整后的TMPRSS6 rs855791与血浆hepcidin浓度差异有统计学意义(p = 0.039),其中G等位基因携带者的hepcidin浓度低于AA纯合子。其他多态性无显著性差异。连锁不平衡(LD)分析显示,HAMP和TMPRSS6基因内相关性强,但基因间相关性不强。这些发现强调了TMPRSS6在铁稳态中的调节作用。这项研究在马来西亚年轻人中提供了第一个特定人群的证据,为支持未来大规模和个性化贫血研究提供了基线遗传数据。
{"title":"The role of rs10414846, rs10421768, rs855791 and rs4820268 polymorphisms in iron-regulatory genes among Malaysian young adults","authors":"Jin-Rou Liew ,&nbsp;Sing-Yan Looi ,&nbsp;Keat-Wei Loo ,&nbsp;Lai-Kuan Teh","doi":"10.1016/j.humgen.2025.201526","DOIUrl":"10.1016/j.humgen.2025.201526","url":null,"abstract":"<div><div>Genetic variants involved in iron-regulatory pathways are important determinants of individual susceptibility to iron deficiency or anaemia. Genetic determinants including the hepcidin antimicrobial peptide (<em>HAMP</em>) and transmembrane serine protease 6 (<em>TMPRSS6</em>) genes play crucial roles in systemic iron regulation. This study investigated the relationship of four single nucleotide polymorphisms (SNPs) [<em>HAMP</em> rs10414846 (C &gt; T), <em>HAMP</em> rs10421768 (A &gt; G), <em>TMPRSS6</em> rs855791 (A &gt; G) and <em>TMPRSS6</em> rs4820268 (G &gt; A)] with haemoglobin (Hb), plasma hepcidin and serum iron levels among Malaysian young adults. A total of 183 unrelated participants aged 18 to 35 years were recruited. Genotyping was conducted using tetra-primer amplification refractory mutation system-polymerase chain reaction (Tetra-ARMS-PCR). Plasma hepcidin concentration and serum iron levels were detected using a human hepcidin ELISA kit and an iron colorimetric assay, respectively. Statistical analyses were performed with the Kruskal-Wallis and Mann-Whitney <em>U</em> tests, followed by general linear model (GLM) adjustments for covariates. Gene-gene interactions were analysed using the Pearson Chi-square (χ<sup>2</sup>) test. A significant difference was observed between <em>TMPRSS6</em> rs855791 and plasma hepcidin concentration after adjustment (<em>p</em> = 0.039), where G allele carriers exhibited lower hepcidin concentration compared with AA homozygotes. No significant differences were observed for the other polymorphisms. Linkage disequilibrium (LD) analysis revealed strong intragenic correlations within <em>HAMP</em> and <em>TMPRSS6</em>, but no intergenic association. These findings highlighted <em>TMPRSS6</em>'s regulatory role in iron homeostasis. This study provides the first population-specific evidence among Malaysian young adults, offering baseline genetic data to support future large-scale and personalised anaemia research.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"47 ","pages":"Article 201526"},"PeriodicalIF":0.7,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promoter methylation signature of SLC16A11 gene reavels poor prognosis in head and neck squamous cell carcinoma SLC16A11基因启动子甲基化特征揭示头颈部鳞状细胞癌预后不良
IF 0.7 Q4 GENETICS & HEREDITY Pub Date : 2025-12-16 DOI: 10.1016/j.humgen.2025.201525
Sonali Awasthi , Tejulal Prasad Chaurasia , Narendra Verma , Satakshi Chaturvedi , Anuradha Kalani , Sudhir Kumar Awasthi , Pramod K. Yadav , Abhijeet Singh , Gyanendra Singh , Rajeev Mishra
Solute carrier (SLC) transporters, which are essential for transporting various metabolites such as carbohydrates, proteins, lipids, and nucleic acids, are often altered in tumor cells to meet their high energy demands. Given the critical role of the SLC transporters in driving metabolism these transporters represent a promising target for cancer therapies and the development of biomarkers to track tumor development and progression. The SLC gene family comprises 14 members, designated SLC16A1 to SLC16A14, which have been implicated in various types of cancer. Their diverse expression patterns are often associated with a poor prognosis across multiple cancers. However, the prognostic significance and mechanisms of the distinct members of the SLC16A gene family in human head and neck squamous cell carcinoma (HNSC) remain unclear. In this study, we explored the SLC16A family members in HNSC using various online genomic databases, including GEPIA2 and TIMER2, to assess the prognostic significance of SLC16A11. Our findings revealed that the expression of the SLC16A11 gene was significantly lower in HNSC tissues compared to normal tissues. We identified that hyper-methylation of the SLC16A11 promoter was associated with decreased expression levels and a poor prognosis in HNSCC, likely due to increased immune infiltration of various immune cells. This study emphasizes the potential of SLC16A11 as a prognostic marker for head and neck squamous cell carcinoma (HNSC) and identifies it as an epigenetically regulated tumor suppressor gene. Overall our research highlights need for further investigation into SLC16A11 as a key metabolic transporter and its potential application in HNSC therapeutics.
溶质载体(SLC)转运蛋白是运输碳水化合物、蛋白质、脂质和核酸等各种代谢物所必需的,在肿瘤细胞中经常发生改变以满足其高能量需求。鉴于SLC转运蛋白在驱动代谢中的关键作用,这些转运蛋白代表了癌症治疗和追踪肿瘤发生和进展的生物标志物的发展的有希望的靶标。SLC基因家族包括14个成员,从SLC16A1到SLC16A14,与多种类型的癌症有关。它们不同的表达模式通常与多种癌症的不良预后有关。然而,SLC16A基因家族不同成员在人头颈部鳞状细胞癌(HNSC)中的预后意义和机制尚不清楚。在这项研究中,我们利用各种在线基因组数据库,包括GEPIA2和TIMER2,探索了SLC16A家族成员在HNSC中,以评估SLC16A11的预后意义。我们的研究结果显示,SLC16A11基因在HNSC组织中的表达明显低于正常组织。我们发现SLC16A11启动子的超甲基化与HNSCC中表达水平降低和预后不良相关,可能是由于各种免疫细胞的免疫浸润增加。本研究强调了SLC16A11作为头颈部鳞状细胞癌(HNSC)预后标志物的潜力,并将其鉴定为一种表观遗传调控的肿瘤抑制基因。总之,我们的研究强调需要进一步研究SLC16A11作为一个关键的代谢转运蛋白及其在HNSC治疗中的潜在应用。
{"title":"Promoter methylation signature of SLC16A11 gene reavels poor prognosis in head and neck squamous cell carcinoma","authors":"Sonali Awasthi ,&nbsp;Tejulal Prasad Chaurasia ,&nbsp;Narendra Verma ,&nbsp;Satakshi Chaturvedi ,&nbsp;Anuradha Kalani ,&nbsp;Sudhir Kumar Awasthi ,&nbsp;Pramod K. Yadav ,&nbsp;Abhijeet Singh ,&nbsp;Gyanendra Singh ,&nbsp;Rajeev Mishra","doi":"10.1016/j.humgen.2025.201525","DOIUrl":"10.1016/j.humgen.2025.201525","url":null,"abstract":"<div><div>Solute carrier (SLC) transporters, which are essential for transporting various metabolites such as carbohydrates, proteins, lipids, and nucleic acids, are often altered in tumor cells to meet their high energy demands. Given the critical role of the SLC transporters in driving metabolism these transporters represent a promising target for cancer therapies and the development of biomarkers to track tumor development and progression. The SLC gene family comprises 14 members, designated SLC16A1 to SLC16A14, which have been implicated in various types of cancer. Their diverse expression patterns are often associated with a poor prognosis across multiple cancers. However, the prognostic significance and mechanisms of the distinct members of the SLC16A gene family in human head and neck squamous cell carcinoma (HNSC) remain unclear. In this study, we explored the SLC16A family members in HNSC using various online genomic databases, including GEPIA2 and TIMER2, to assess the prognostic significance of SLC16A11. Our findings revealed that the expression of the SLC16A11 gene was significantly lower in HNSC tissues compared to normal tissues. We identified that hyper-methylation of the SLC16A11 promoter was associated with decreased expression levels and a poor prognosis in HNSCC, likely due to increased immune infiltration of various immune cells. This study emphasizes the potential of SLC16A11 as a prognostic marker for head and neck squamous cell carcinoma (HNSC) and identifies it as an epigenetically regulated tumor suppressor gene. Overall our research highlights need for further investigation into SLC16A11 as a key metabolic transporter and its potential application in HNSC therapeutics.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"47 ","pages":"Article 201525"},"PeriodicalIF":0.7,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145790125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Connection between epithelial-mesenchymal transition and cancer stem cells and the potential therapeutic strategies 上皮-间质转化与癌症干细胞的关系及潜在的治疗策略
IF 0.7 Q4 GENETICS & HEREDITY Pub Date : 2025-12-11 DOI: 10.1016/j.humgen.2025.201524
Jingxuan Xu , Jiaxin Geng , Jingyuan Ma , Yaofan Lu , Fuyuan Ma , Yuan Qin , Biao Huang
Cancer prevalence is on the rise globally. Early detection, targeted treatments, immunotherapies, and routine chemotherapies are vital for cancer management and patient survival extension, yet complete cancer eradication remains a significant challenge. The epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) are central to cancer cell metastasis, apoptosis resistance, tumor relapse, and drug resistance. This review focuses on the molecular mechanisms of EMT and CSCs, their interdependencies, the implicated signaling cascades, and the function of microRNA (miRNA) in EMT and CSC initiation regulation. EMT can endow cancer cells with mesenchymal characteristics and the capacity to transition into a CSC state; notably, CSCs can also reinforce EMT progression through secreting cytokines like transforming growth factor-β (TGF-β), forming a reciprocal regulatory loop that sustains tumor aggressiveness. These processes are intricately linked to the TGF-β, Wnt, and Notch signaling pathways, as well as miRNA expression. Advancing cancer treatment modalities and pinpointing novel therapeutic targets necessitate deeper exploration of the EMT-CSC connection. Consequently, crafting therapeutic approaches that target EMT or CSCs holds promise for enhancing cancer treatment efficacy.
全球癌症患病率呈上升趋势。早期发现、靶向治疗、免疫治疗和常规化疗对癌症管理和延长患者生存至关重要,但完全根除癌症仍然是一个重大挑战。上皮-间质转化(EMT)和癌症干细胞(CSCs)是癌细胞转移、细胞凋亡抵抗、肿瘤复发和耐药的核心。本文就EMT和CSC的分子机制、相互依赖性、相关信号级联以及microRNA (miRNA)在EMT和CSC起始调控中的作用进行综述。EMT可以使癌细胞具有间充质特性,并具有向CSC状态转变的能力;值得注意的是,CSCs还可以通过分泌转化生长因子-β (TGF-β)等细胞因子来促进EMT的进展,形成一个维持肿瘤侵袭性的互惠调节回路。这些过程与TGF-β、Wnt和Notch信号通路以及miRNA表达有着复杂的联系。推进癌症治疗模式和确定新的治疗靶点需要对EMT-CSC连接进行更深入的探索。因此,制定针对EMT或CSCs的治疗方法有望提高癌症治疗效果。
{"title":"Connection between epithelial-mesenchymal transition and cancer stem cells and the potential therapeutic strategies","authors":"Jingxuan Xu ,&nbsp;Jiaxin Geng ,&nbsp;Jingyuan Ma ,&nbsp;Yaofan Lu ,&nbsp;Fuyuan Ma ,&nbsp;Yuan Qin ,&nbsp;Biao Huang","doi":"10.1016/j.humgen.2025.201524","DOIUrl":"10.1016/j.humgen.2025.201524","url":null,"abstract":"<div><div>Cancer prevalence is on the rise globally. Early detection, targeted treatments, immunotherapies, and routine chemotherapies are vital for cancer management and patient survival extension, yet complete cancer eradication remains a significant challenge. The epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) are central to cancer cell metastasis, apoptosis resistance, tumor relapse, and drug resistance. This review focuses on the molecular mechanisms of EMT and CSCs, their interdependencies, the implicated signaling cascades, and the function of microRNA (miRNA) in EMT and CSC initiation regulation. EMT can endow cancer cells with mesenchymal characteristics and the capacity to transition into a CSC state; notably, CSCs can also reinforce EMT progression through secreting cytokines like transforming growth factor-β (TGF-β), forming a reciprocal regulatory loop that sustains tumor aggressiveness. These processes are intricately linked to the TGF-β, Wnt, and Notch signaling pathways, as well as miRNA expression. Advancing cancer treatment modalities and pinpointing novel therapeutic targets necessitate deeper exploration of the EMT-CSC connection. Consequently, crafting therapeutic approaches that target EMT or CSCs holds promise for enhancing cancer treatment efficacy.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"47 ","pages":"Article 201524"},"PeriodicalIF":0.7,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hippo/YAP Signaling in cataract pathogenesis: Mechanistic insights and emerging therapeutic strategies 白内障发病机制中的Hippo/YAP信号:机制见解和新兴治疗策略
IF 0.7 Q4 GENETICS & HEREDITY Pub Date : 2025-12-08 DOI: 10.1016/j.humgen.2025.201522
Meraj Khan, Lokesh Verma
Cataracts represent a primary cause of visual impairment, arising from the opacification of the eye's crystalline lens. These can be categorized etiologically as congenital, age-related, or secondary, and clinically as cortical or nuclear, based on the location of the opacification. The Hippo/YAP signaling pathway is a fundamental cellular mechanism that governs lens epithelial cell (LEC) behavior, and its dysregulation is a key factor in cataract formation. Abnormalities in this pathway disrupt LEC proliferation and differentiation, leading to lens opacification. The effector protein YAP plays a crucial role in lens pathology, including posterior capsule opacification (PCO) and epithelial-mesenchymal transition (EMT). To address this, current research is exploring novel therapies that target the Hippo/YAP pathway to counteract these processes. These innovative approaches include using small molecule inhibitors, such as verteporfin, to disrupt YAP's function, as well as RNA-based therapies that target non-coding RNAs like lncRNA-MIAT to suppress LEC proliferation. Furthermore, gene-editing technologies like CRISPR/Cas9 are being explored to correct genetic defects associated with cataracts, such as mutations in GJA8. These molecularly targeted interventions represent a paradigm shift in cataract management, aiming to prevent the condition and improve patient outcomes. However, thorough validation is necessary to ensure their safety and efficacy for clinical application.
白内障是由眼睛晶状体混浊引起的,是视力受损的主要原因。根据混浊的位置,在病因学上可分为先天性、年龄相关性或继发性,在临床上可分为皮质性或核性。Hippo/YAP信号通路是控制晶状体上皮细胞(LEC)行为的基本细胞机制,其失调是白内障形成的关键因素。该通路的异常破坏LEC的增殖和分化,导致晶状体混浊。效应蛋白YAP在晶状体病理中起着至关重要的作用,包括后囊膜混浊(PCO)和上皮-间质转化(EMT)。为了解决这个问题,目前的研究正在探索针对Hippo/YAP通路的新疗法来抵消这些过程。这些创新的方法包括使用小分子抑制剂,如维替波芬,来破坏YAP的功能,以及靶向非编码rna(如lncRNA-MIAT)的基于rna的疗法来抑制LEC增殖。此外,人们正在探索CRISPR/Cas9等基因编辑技术,以纠正与白内障相关的遗传缺陷,例如GJA8突变。这些分子靶向干预措施代表了白内障管理的范式转变,旨在预防病情和改善患者的预后。然而,为了确保其临床应用的安全性和有效性,需要进行彻底的验证。
{"title":"Hippo/YAP Signaling in cataract pathogenesis: Mechanistic insights and emerging therapeutic strategies","authors":"Meraj Khan,&nbsp;Lokesh Verma","doi":"10.1016/j.humgen.2025.201522","DOIUrl":"10.1016/j.humgen.2025.201522","url":null,"abstract":"<div><div>Cataracts represent a primary cause of visual impairment, arising from the opacification of the eye's crystalline lens. These can be categorized etiologically as congenital, age-related, or secondary, and clinically as cortical or nuclear, based on the location of the opacification. The Hippo/YAP signaling pathway is a fundamental cellular mechanism that governs lens epithelial cell (LEC) behavior, and its dysregulation is a key factor in cataract formation. Abnormalities in this pathway disrupt LEC proliferation and differentiation, leading to lens opacification. The effector protein YAP plays a crucial role in lens pathology, including posterior capsule opacification (PCO) and epithelial-mesenchymal transition (EMT). To address this, current research is exploring novel therapies that target the Hippo/YAP pathway to counteract these processes. These innovative approaches include using small molecule inhibitors, such as verteporfin, to disrupt YAP's function, as well as RNA-based therapies that target non-coding RNAs like lncRNA-MIAT to suppress LEC proliferation. Furthermore, gene-editing technologies like CRISPR/Cas9 are being explored to correct genetic defects associated with cataracts, such as mutations in GJA8. These molecularly targeted interventions represent a paradigm shift in cataract management, aiming to prevent the condition and improve patient outcomes. However, thorough validation is necessary to ensure their safety and efficacy for clinical application.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"47 ","pages":"Article 201522"},"PeriodicalIF":0.7,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145790126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring Parkinson's disease: Insights from genetic biomarkers and protein-protein interactions 探索帕金森病:来自遗传生物标志物和蛋白质-蛋白质相互作用的见解
IF 0.7 Q4 GENETICS & HEREDITY Pub Date : 2025-12-08 DOI: 10.1016/j.humgen.2025.201523
Zahra Parani , Yeganeh Sorayaei , Mohammad Shokrzadeh , Nargess Abdali , Elham Rismani
Parkinson's disease (PD) ranks as the second most prevalent neurodegenerative disorder, primarily characterized by motor dysfunction resulting from the degeneration of dopaminergic neurons. Early and accurate diagnosis is crucial for effective treatment; however, the overlap of symptoms with other disorders frequently results in misdiagnosis. This study aims to identify reliable biomarkers for the early PD diagnosis through a comprehensive literature review and bioinformatics analysis. We initially identified 32 genes strongly associated with PD, from published studies and database annotations. Further bioinformatics validation using protein-protein interaction networks and external gene expression datasets revealed additional candidate genes, including GBA1 and LRRK2, which are relevant to both familial and sporadic forms of PD. Enrichment analyses of these genes, emphasizing pathways related to mitochondrial function, autophagy and neurodegeneration-related pathways. Our findings highlight the promise of genetic biomarkers in improving diagnostic precision and guiding therapeutic approaches, thereby enhancing clinical outcomes for patients with PD. Ongoing validation of these results is essential for integrating biomarkers into standard clinical practice, with the ultimate goal of revolutionizing the diagnosis and management of PD.
帕金森病(PD)是第二大常见的神经退行性疾病,主要特征是多巴胺能神经元变性导致的运动功能障碍。早期和准确的诊断对于有效治疗至关重要;然而,症状与其他疾病的重叠经常导致误诊。本研究旨在通过全面的文献综述和生物信息学分析,寻找可靠的PD早期诊断的生物标志物。我们最初从已发表的研究和数据库注释中确定了32个与帕金森病密切相关的基因。利用蛋白相互作用网络和外部基因表达数据集进一步的生物信息学验证揭示了其他候选基因,包括GBA1和LRRK2,它们与家族性和散发性PD相关。富集分析这些基因,强调与线粒体功能、自噬和神经变性相关的途径。我们的研究结果强调了遗传生物标志物在提高诊断精度和指导治疗方法方面的前景,从而提高了PD患者的临床结果。这些结果的持续验证对于将生物标志物纳入标准临床实践至关重要,最终目标是彻底改变PD的诊断和管理。
{"title":"Exploring Parkinson's disease: Insights from genetic biomarkers and protein-protein interactions","authors":"Zahra Parani ,&nbsp;Yeganeh Sorayaei ,&nbsp;Mohammad Shokrzadeh ,&nbsp;Nargess Abdali ,&nbsp;Elham Rismani","doi":"10.1016/j.humgen.2025.201523","DOIUrl":"10.1016/j.humgen.2025.201523","url":null,"abstract":"<div><div>Parkinson's disease (PD) ranks as the second most prevalent neurodegenerative disorder, primarily characterized by motor dysfunction resulting from the degeneration of dopaminergic neurons. Early and accurate diagnosis is crucial for effective treatment; however, the overlap of symptoms with other disorders frequently results in misdiagnosis. This study aims to identify reliable biomarkers for the early PD diagnosis through a comprehensive literature review and bioinformatics analysis. We initially identified 32 genes strongly associated with PD, from published studies and database annotations. Further bioinformatics validation using protein-protein interaction networks and external gene expression datasets revealed additional candidate genes, including GBA1 and LRRK2, which are relevant to both familial and sporadic forms of PD. Enrichment analyses of these genes, emphasizing pathways related to mitochondrial function, autophagy and neurodegeneration-related pathways. Our findings highlight the promise of genetic biomarkers in improving diagnostic precision and guiding therapeutic approaches, thereby enhancing clinical outcomes for patients with PD. Ongoing validation of these results is essential for integrating biomarkers into standard clinical practice, with the ultimate goal of revolutionizing the diagnosis and management of PD.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"47 ","pages":"Article 201523"},"PeriodicalIF":0.7,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145736910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of key players in drug resistant colon cancer - An integrative network pharmacology approach 鉴定耐药结肠癌的关键因素-综合网络药理学方法
IF 0.7 Q4 GENETICS & HEREDITY Pub Date : 2025-12-03 DOI: 10.1016/j.humgen.2025.201521
Jeevitha Priya Manoharan , Neha Saravanakumar , Hema Palanisamy , Subramanian Vidyalakshmi
Multi Drug Resistance (MDR) of cancer cells is the most important cause for the failure of chemotherapy in treating cancer patients. Hence, identification of appropriate drug resistance biomarkers is the need of the hour to optimize treatment regimen. The goal of this study is to identify critical genes and pathways that could be used to predict the drug resistance in colon cancer patients. In this study, gene expression datasets of colon cancer patients and cell lines treated with 5-fluorouracil, irinotecan and oxaliplatin were obtained. Differential gene expression analysis was performed and the hub genes associated with drug resistance were identified through network analysis. The functional and pathway enrichment of the genes were performed. ABCC4, AKR1C3, CASP3, CASP4, IFITM1, IFITM2, IFITM3, IFI6, IFI44, IFI16, IFI27 and SLC1A7 were found to be highly interacting (Hub) genes in the network analysis. Two significant modules were predicted in the generated network by module analysis. The genes of module 2 were observed to be highly interacting with each other in the pathway cross talk analysis. Among the identified genes, IFI44 was significantly associated with the patients' overall survival. In addition, IFI44 found to be associated with immune infiltration in the tumor microenvironment. In addition, B-cell receptor signalling pathway, galactose metabolism, steroid hormone biosynthesis and folate biosynthesis pathway can be targeted for improving the efficacy of chemotherapeutic drugs, while treating multidrug resistant colon cancer. Hence, IFI44 could be used as a biomarker for identifying drug resistance. Further, experimental studies are required to validate our findings.
肿瘤细胞的耐多药(MDR)是导致化疗失败的最重要原因。因此,确定适当的耐药生物标志物是优化治疗方案的需要。本研究的目的是确定可用于预测结肠癌患者耐药性的关键基因和途径。本研究获得了5-氟尿嘧啶、伊立替康和奥沙利铂治疗的结肠癌患者和细胞系的基因表达数据集。进行差异基因表达分析,通过网络分析鉴定与耐药相关的枢纽基因。对这些基因进行功能富集和途径富集。网络分析发现ABCC4、AKR1C3、CASP3、CASP4、IFITM1、IFITM2、IFITM3、IFI6、IFI44、IFI16、IFI27和SLC1A7是高互作(Hub)基因。通过模块分析,在生成的网络中预测出两个显著的模块。在通路串扰分析中,发现模块2的基因之间存在高度相互作用。在已鉴定的基因中,IFI44与患者的总生存率显著相关。此外,发现IFI44与肿瘤微环境中的免疫浸润有关。此外,b细胞受体信号通路、半乳糖代谢、类固醇激素生物合成和叶酸生物合成途径可以作为提高化疗药物疗效的靶点,同时治疗多重耐药结肠癌。因此,IFI44可作为鉴定耐药的生物标志物。此外,还需要实验研究来验证我们的发现。
{"title":"Identification of key players in drug resistant colon cancer - An integrative network pharmacology approach","authors":"Jeevitha Priya Manoharan ,&nbsp;Neha Saravanakumar ,&nbsp;Hema Palanisamy ,&nbsp;Subramanian Vidyalakshmi","doi":"10.1016/j.humgen.2025.201521","DOIUrl":"10.1016/j.humgen.2025.201521","url":null,"abstract":"<div><div>Multi Drug Resistance (MDR) of cancer cells is the most important cause for the failure of chemotherapy in treating cancer patients. Hence, identification of appropriate drug resistance biomarkers is the need of the hour to optimize treatment regimen. The goal of this study is to identify critical genes and pathways that could be used to predict the drug resistance in colon cancer patients. In this study, gene expression datasets of colon cancer patients and cell lines treated with 5-fluorouracil, irinotecan and oxaliplatin were obtained. Differential gene expression analysis was performed and the hub genes associated with drug resistance were identified through network analysis. The functional and pathway enrichment of the genes were performed. ABCC4, AKR1C3, CASP3, CASP4, IFITM1, IFITM2, IFITM3, IFI6, IFI44, IFI16, IFI27 and SLC1A7 were found to be highly interacting (Hub) genes in the network analysis. Two significant modules were predicted in the generated network by module analysis. The genes of module 2 were observed to be highly interacting with each other in the pathway cross talk analysis. Among the identified genes, IFI44 was significantly associated with the patients' overall survival. In addition, IFI44 found to be associated with immune infiltration in the tumor microenvironment. In addition, B-cell receptor signalling pathway, galactose metabolism, steroid hormone biosynthesis and folate biosynthesis pathway can be targeted for improving the efficacy of chemotherapeutic drugs, while treating multidrug resistant colon cancer. Hence, IFI44 could be used as a biomarker for identifying drug resistance. Further, experimental studies are required to validate our findings.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"47 ","pages":"Article 201521"},"PeriodicalIF":0.7,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondrial ND3, tRNA (Leu) and hypervariable region I: Variants in type II diabetes patients from the central rural Indian population. 线粒体ND3、tRNA (Leu)和高变区I:印度中部农村人口II型糖尿病患者的变异
IF 0.7 Q4 GENETICS & HEREDITY Pub Date : 2025-11-29 DOI: 10.1016/j.humgen.2025.201520
Tejas Tajane , Mamata Chandrakar , Prafulla Ambulkar , Pranita Waghmare , Bharati Taksande , Jwalant Waghmare
Diabetes is a lifestyle disorder with the highest mortality rate, and mitochondria play a crucial role in the susceptibility and severity of diabetes. This study examined the relationship between mitochondrial genomic variants and lifestyle factors in patients with type 2 diabetes (T2D) within a rural central Indian population. We enrolled 156 participants with diabetes and 108 healthy participants, analysing their anthropometric measurements, lifestyle habits, and mitochondrial DNA (mtDNA) variants. A total of 74 variants were identified, with the D-loop region showing the highest mutation rates. When correlated with BMI, waist-to-hip ratio, and sedentary behaviour, these factors were significantly higher in the diabetes group than in the control group. The variants A10398G and C10400T in ND3 and C16223T in the D-loop were significantly associated with T2D, while T16093C and A3384G were more common in healthy controls, indicating a protective role. Analysing haplogroups revealed that the M haplogroup was the most prevalent, followed by U and H, with H being significantly more common in the healthy group. Additionally, lifestyle factors such as a high-carbohydrate diet and tobacco use contributed to disease progression. This study underscores that certain novel variants are linked to decreased susceptibility to T2D and highlights the complex interaction between mtDNA variants, lifestyle factors, and T2D in the Indian population.
糖尿病是一种死亡率最高的生活方式疾病,线粒体在糖尿病的易感性和严重程度中起着至关重要的作用。本研究调查了印度中部农村人口中2型糖尿病(T2D)患者线粒体基因组变异与生活方式因素之间的关系。我们招募了156名糖尿病患者和108名健康参与者,分析了他们的人体测量值、生活习惯和线粒体DNA (mtDNA)变异。共鉴定出74个变异,其中D-loop区域的突变率最高。当与身体质量指数、腰臀比和久坐行为相关时,糖尿病组的这些因素明显高于对照组。ND3中的A10398G和C10400T以及D-loop中的C16223T变异与T2D显著相关,而T16093C和A3384G在健康对照中更为常见,表明其具有保护作用。单倍群分析显示,M单倍群最为普遍,其次是U和H,其中H在健康人群中更为常见。此外,高碳水化合物饮食和吸烟等生活方式因素也会导致疾病进展。这项研究强调了某些新的变异与T2D易感性降低有关,并强调了mtDNA变异、生活方式因素和印度人群中T2D之间复杂的相互作用。
{"title":"Mitochondrial ND3, tRNA (Leu) and hypervariable region I: Variants in type II diabetes patients from the central rural Indian population.","authors":"Tejas Tajane ,&nbsp;Mamata Chandrakar ,&nbsp;Prafulla Ambulkar ,&nbsp;Pranita Waghmare ,&nbsp;Bharati Taksande ,&nbsp;Jwalant Waghmare","doi":"10.1016/j.humgen.2025.201520","DOIUrl":"10.1016/j.humgen.2025.201520","url":null,"abstract":"<div><div>Diabetes is a lifestyle disorder with the highest mortality rate, and mitochondria play a crucial role in the susceptibility and severity of diabetes. This study examined the relationship between mitochondrial genomic variants and lifestyle factors in patients with type 2 diabetes (T2D) within a rural central Indian population. We enrolled 156 participants with diabetes and 108 healthy participants, analysing their anthropometric measurements, lifestyle habits, and mitochondrial DNA (mtDNA) variants. A total of 74 variants were identified, with the D-loop region showing the highest mutation rates. When correlated with BMI, waist-to-hip ratio, and sedentary behaviour, these factors were significantly higher in the diabetes group than in the control group. The variants A10398G and C10400T in ND3 and C16223T in the D-loop were significantly associated with T2D, while T16093C and A3384G were more common in healthy controls, indicating a protective role. Analysing haplogroups revealed that the M haplogroup was the most prevalent, followed by U and H, with H being significantly more common in the healthy group. Additionally, lifestyle factors such as a high-carbohydrate diet and tobacco use contributed to disease progression. This study underscores that certain novel variants are linked to decreased susceptibility to T2D and highlights the complex interaction between mtDNA variants, lifestyle factors, and T2D in the Indian population.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"47 ","pages":"Article 201520"},"PeriodicalIF":0.7,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of DVWA (rs7639618) gene polymorphisms with knee osteoarthritis susceptibility: An updated systematic review and meta-analysis DVWA (rs7639618)基因多态性与膝骨关节炎易感性的关联:一项最新的系统综述和荟萃分析
IF 0.7 Q4 GENETICS & HEREDITY Pub Date : 2025-11-28 DOI: 10.1016/j.humgen.2025.201519
Annamalai R , Venkatramanaiah C , Marimuthu Raja , Santhosh Kumar Yasam , Sujhithra A , Catherine Rexy , Vignesh Narasimman , D. Danis Vijay

Background & aim

Knee osteoarthritis (KOA)1 is a common degenerative joint disease characterized by progressive cartilage breakdown that leads to pain and reduced mobility. Although genetic predisposition including the double von Willebrand factor A (DVWA; rs7639618) gene polymorphism has been implicated in KOA, previous case–control studies have reported inconsistent findings. This updated meta-analysis aims to clarify the association between the DVWA (rs7639618) gene polymorphism and KOA susceptibility.

Materials & methods

A systematic search was performed in Pub Med, Web of Science, Science Direct, and Google Scholar for case–control studies published up to June 2025. Eligible studies reported genotype and allele distributions for rs7639618 in KOA cases and controls. Study quality was assessed using the Newcastle–Ottawa Scale (NOS).2 Odds ratios (ORs)3 with 95 % confidence intervals (CIs)4 were calculated under allele, recessive, dominant, and over-dominant models. Heterogeneity was evaluated using the Q test and I2 statistic, and random- or fixed-effects models were applied accordingly. Subgroup analyses were conducted by ethnicity, and publication bias was assessed with funnel plots and Egger's test. Sensitivity analysis was carried out by excluding each study.

Results

Thirteen studies comprising 7110 KOA cases and 6931 controls were included. Pooled analyses across all genetic models showed no statistically significant association between rs7639618 and KOA susceptibility. For the allele contrast model, the overall OR was 1.03 (95 % CI: 0.90–1.19); for the recessive model, OR was 1.06 (95 % CI: 0.90–1.25); for the dominant model, OR was 1.08 (95 % CI: 0.85–1.38); and for the over-dominant model, OR was 0.98 (95 % CI: 0.91–1.05). Subgroup analyses revealed no increased risk in either Asian or Caucasian populations. Sensitivity analysis confirmed the stability of the results, and no significant publication bias was detected.

Conclusion

The findings of this meta-analysis suggest that the DVWA (rs7639618) polymorphism is not significantly associated with KOA susceptibility in the overall population or within specific ethnic groups. Despite the rigorous methodology and comprehensive analysis, the presence of substantial heterogeneity in some genetic models underscores the need for further well-designed, large-scale studies across diverse populations.
膝关节骨关节炎(KOA)1是一种常见的退行性关节疾病,其特征是进行性软骨破裂,导致疼痛和活动能力降低。虽然包括双血管性血液病因子A (DVWA; rs7639618)基因多态性在内的遗传易感性与KOA有关,但先前的病例对照研究报告的结果不一致。这项更新的荟萃分析旨在阐明DVWA (rs7639618)基因多态性与KOA易感性之间的关系。材料&方法系统检索Pub Med、Web of Science、Science Direct和b谷歌Scholar,检索截至2025年6月发表的病例对照研究。符合条件的研究报告了rs7639618在KOA病例和对照组中的基因型和等位基因分布。采用纽卡斯尔-渥太华量表(NOS)评估研究质量在等位基因、隐性、显性和过显性模型下计算优势比(ORs)和95%置信区间(ci)。采用Q检验和I2统计量评估异质性,并相应采用随机或固定效应模型。按种族进行亚组分析,用漏斗图和Egger检验评估发表偏倚。通过排除每项研究进行敏感性分析。结果纳入13项研究,7110例KOA病例和6931例对照。所有遗传模型的汇总分析显示,rs7639618与KOA易感性之间没有统计学意义上的关联。对于等位基因对比模型,总体OR为1.03 (95% CI: 0.90-1.19);对于隐性模型,OR为1.06 (95% CI: 0.90-1.25);优势模型OR为1.08 (95% CI: 0.85-1.38);对于过优势模型,OR为0.98 (95% CI: 0.91-1.05)。亚组分析显示,无论是亚洲人还是高加索人,风险都没有增加。敏感性分析证实了结果的稳定性,未发现明显的发表偏倚。结论本荟萃分析结果提示,DVWA (rs7639618)多态性与KOA易感性在总体人群或特定族群中均无显著相关性。尽管有严格的方法和全面的分析,但在一些遗传模型中存在实质性的异质性,这强调了进一步在不同人群中进行精心设计的大规模研究的必要性。
{"title":"Association of DVWA (rs7639618) gene polymorphisms with knee osteoarthritis susceptibility: An updated systematic review and meta-analysis","authors":"Annamalai R ,&nbsp;Venkatramanaiah C ,&nbsp;Marimuthu Raja ,&nbsp;Santhosh Kumar Yasam ,&nbsp;Sujhithra A ,&nbsp;Catherine Rexy ,&nbsp;Vignesh Narasimman ,&nbsp;D. Danis Vijay","doi":"10.1016/j.humgen.2025.201519","DOIUrl":"10.1016/j.humgen.2025.201519","url":null,"abstract":"<div><h3>Background &amp; aim</h3><div>Knee osteoarthritis (KOA)<span><span><sup>1</sup></span></span> is a common degenerative joint disease characterized by progressive cartilage breakdown that leads to pain and reduced mobility. Although genetic predisposition including the double von Willebrand factor A (DVWA; rs7639618) gene polymorphism has been implicated in KOA, previous case–control studies have reported inconsistent findings. This updated meta-analysis aims to clarify the association between the DVWA (rs7639618) gene polymorphism and KOA susceptibility.</div></div><div><h3>Materials &amp; methods</h3><div>A systematic search was performed in Pub Med, Web of Science, Science Direct, and Google Scholar for case–control studies published up to June 2025. Eligible studies reported genotype and allele distributions for rs7639618 in KOA cases and controls. Study quality was assessed using the Newcastle–Ottawa Scale (NOS).<span><span><sup>2</sup></span></span> Odds ratios (ORs)<span><span><sup>3</sup></span></span> with 95 % confidence intervals (CIs)<span><span><sup>4</sup></span></span> were calculated under allele, recessive, dominant, and over-dominant models. Heterogeneity was evaluated using the Q test and I<sup>2</sup> statistic, and random- or fixed-effects models were applied accordingly. Subgroup analyses were conducted by ethnicity, and publication bias was assessed with funnel plots and Egger's test. Sensitivity analysis was carried out by excluding each study.</div></div><div><h3>Results</h3><div>Thirteen studies comprising 7110 KOA cases and 6931 controls were included. Pooled analyses across all genetic models showed no statistically significant association between rs7639618 and KOA susceptibility. For the allele contrast model, the overall OR was 1.03 (95 % CI: 0.90–1.19); for the recessive model, OR was 1.06 (95 % CI: 0.90–1.25); for the dominant model, OR was 1.08 (95 % CI: 0.85–1.38); and for the over-dominant model, OR was 0.98 (95 % CI: 0.91–1.05). Subgroup analyses revealed no increased risk in either Asian or Caucasian populations. Sensitivity analysis confirmed the stability of the results, and no significant publication bias was detected.</div></div><div><h3>Conclusion</h3><div>The findings of this meta-analysis suggest that the DVWA (rs7639618) polymorphism is not significantly associated with KOA susceptibility in the overall population or within specific ethnic groups. Despite the rigorous methodology and comprehensive analysis, the presence of substantial heterogeneity in some genetic models underscores the need for further well-designed, large-scale studies across diverse populations.</div></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"47 ","pages":"Article 201519"},"PeriodicalIF":0.7,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Human Gene
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1